Shopping Cart
- Remove All
Your shopping cart is currently empty
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $1,320 | Backorder | |
| 10 mg | $2,150 | Backorder |
| Description | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2]. |
| In vitro | Trastuzumab emtansine (2 μg/mL; 3 d) markedly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2]. |
| In vivo | Trastuzumab emtansine (15 mg/kg; i.v., three to five times weekly for 3 weeks) demonstrates significant anti-tumor effects in CB-17/SCID mice (6 weeks) injected with OVA10 cells[2]. |
| Synonyms | T-DM1 |
| Formula | N/A |
| Cas No. | 1018448-65-1 |
| Storage | keep away from direct sunlight | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.